Next-Generation Biologics Market Forecast to 2029

1. Report Overview 1.1 Overview of the Next-Generation Biologics Market 1.2 Why You Should Read This Report 1.3 How This Report Delivers 1.4 Main Questions Answered by This Analytical Study 1.5 Who is This Report For? 1.6 Methodology 1.7 Frequently Asked Questions (FAQ) 1.8 Associated Reports 1.9 About Visiongain 2. Introduction to Next-Generation Biologics 2.1 Brief History of Biological Drug Development 2.1.1 Limitations of Present-Generation Biological Drugs 2.2 The Promise of Next-Generation Biologics 2.2.1 Defining Next-Generation Biologics 2.2.1.1 A Definition of Regenerative Medicine 2.2.1.2 Extending Half-Life: Pegylation and Other Novel Strategies 3. World Next-Generation Biologics Market: Outlook and Forecast to 2029 3.1 The Next-Generation Biologics Market 2018 3.1.1 Development of the Next-Generation Biologics Market 2009-2016 3.1.2 Rising Demand for Biological Therapies 3.1.3 Next-Generation Drugs as a Share of the Biologics Market 2018 3.1.4 Main Sectors of the Next-Generation Biologics Market: Antibodies and Regenerative Medicine Lead the Way 3.1.5 Leading Companies in the Next-Generation Biologics Market 2018 3.2 The Next-Generation Biologics Market 2019-2029 3.2.1 Growth Drivers for Biological Drug Revenues 2019-2029 3.2.2 Global Next-Generation Biologics Market Forecast 2019-2029 3.2.3 Product Launches in All Sectors to Drive Market Growth 2019-2029 3.2.4 Next-Generation Biologics: Market Restraints 2019-2029 3.2.5 Rising Market Shares for Next-Generation Insulins 2019-2029 4. Regional Submarkets for Next-Generation Biologics Forecast to 2029 4.1 National Submarket Forecasts 2019-2029 4.1.1 How Will National Submarket Shares Change to 2029? 4.2 Rising Disease Incidence in Important Markets 2019-2029 4.3 Approval of Next-Generation Biologics in Leading National Submarkets 4.4 North America Next-Generation Biologics Market 2019-2029 4.4.1 US Will be the Largest Submarket for Next-Generation Biologics 2019-2029 4.4.2 Canada Next-Generation Biologics Market 2019-2029 4.5 European Next-Generation Biologics Market 2019-2029 4.5.1 Regenerative Medicine Development in the EU 4.5.2 Market Access for Next-Generation Biologics in the EU 4.5.3 Germany: Submarket Forecast 2019-2029 4.5.4 UK: Submarket Forecast 2019-2029 4.5.5 France: Submarket Forecast 2019-2029 4.5.6 Italy and Spain: Submarket Forecasts 2019-2029 4.6 Asia Pacific Next-Generation Biologics 2019-2029 4.6.1 Japan Next-Generation Biologics Market 2019-2029 4.6.1.1 National Expertise in Stem Cell Research 4.6.1.2 Japanese Submarket Forecast 2019-2029 4.6.2 Chinese Submarket Forecast 2019-2029 4.6.3 Indian Submarket Forecast 2019-2029 4.7 RoW Next-Generation Biologics Markets 2019-2029 4.7.1 Brazil Next-Generation Biologics Market 2019-2029 4.7.2 Mexico Next-Generation Biologics Market 2019-2029 4.7.3 Russia Next-Generation Biologics Market 2019-2029 4.7.4 South Africa Next-Generation Biologics Market 2019-2029 5. Next-Generation Antibodies: Submarket Outlooks to 2029 5.1 Strategies for Improving Antibody Therapies 5.1.1 Antibody-Drug Conjugates: Targeted Cytotoxic Therapies 5.1.2 Engineering Antibodies for Improved Potency 5.1.3 Bispecific Antibodies 5.2 Next-Generation Antibody Therapy Submarket 5.3 Next-Generation Antibody Therapy Submarket 2019-2029 5.3.1 Strong Revenue Growth for Next-Generation Antibodies 2019-2029 5.3.2 Blockbuster Potential Will Drive Growth to 2029: Kadcyla, Adcetris and Cosentyx 5.3.3 Next-Generation Antibodies: Submarket Restraints 2019-2029 5.4 Antibody-Drug Conjugates (ADC) Submarket 2019-2029 5.4.1 Antibody-Drug Conjugates Submarket Forecast 2019-2029 5.4.1.1 Kadcyla and Adcetris: Revenue Forecast 2019-2029 5.4.2 What Will Drive Growth for ACDs to 2029 5.4.3 A Long Pipeline of ADCs in Clinical Development 5.4.3.1 CMC544 (Pfizer): NHL Development Halted but Trials in ALL Continue 5.4.3.2 NKTR-102 (Nektar Therapeutics): Phase III for Metastatic Breast Cancer 5.4.3.3 IMGN853 (Immunogen): Phase III for Ovarian Cancer 5.4.3.4 SGN-CD33A (Seattle Genetics): Phase III for Acute myeloid leukemia 5.4.3.5 Rova-T (Abbvie): Phase III for SCLC 5.4.3.6 CDX-011: Potential for Accelerated Approval in Breast Cancer 5.5 Engineered Antibodies Submarket 2019-2029 5.5.1 Engineered Antibodies Submarket Forecast 2019-2029 5.5.1.1 Gazvya Will Lead the Submarket by 2029 5.5.2 Portfolio Management to Drive Growth 2019-2029 5.5.3 Engineered Antibodies Pipeline 2018 5.5.3.1 Benralizumab (MedImmune/Kyowa Hakko Kirin) 5.6 Bispecific Antibodies Submarket 2019-2029 5.6.1 Bispecific Antibodies Submarket Forecast 2019-2029 5.6.2 Bispecific Antibodies: Submarket Drivers and Restraints 2019-2029 5.6.3 One New Approval and Two Phase II Bispecific Antibodies in 2018 5.6.3.1 Blincyto (Amgen): The Second Approved Bispecific Antibody 6. Antibody Fragments and Novel Antibody-like Drugs: Commercial Potential to 2029 6.1 Next-Generation Antibody Fragments: Beyond Fab Fragments 6.1.1 Antibody-Like Proteins Mimic Antibody Therapies 6.1.2 There are Advantages to Using Fragments and Novel Scaffolds 6.2 Antibody Fragment and ALP Submarket 2019-2029 6.2.1 Antibody Fragment and ALP Submarket Forecast 2019-2029 6.2.2 Pharma is Investing Strongly in Antibody Fragments and ALPs 6.2.3 Limited Late-Stage R&D Pipeline to Restrain Growth to 2029 6.3 Outlook for Next-Generation Antibody Fragments 2019-2029 6.3.1 Next-Generation Antibody Fragment Submarket Forecast 2019-2029 6.3.2 One Platform Leads the Pipeline in 2018 6.3.2.1 Three Nanobodies in Development for Rheumatoid Arthritis 6.3.2.2 Caplacizumab (Ablynx): Targeting an Orphan Indication 6.4 The Antibody-Like Protein Submarket 2019-2029 6.4.1 Antibody-Like Protein Submarket Forecast 2019-2029 6.4.2 Four ALPs in Clinical Development in 2018 6.4.2.1 Abicipar Pegol (Allergan/Molecular Partners): Development of the Lead Clinical ALP Delayed 6.5 Will Next-Generation Immunotoxins Change the Market to 2029? 6.5.1 Challenges with First Generation Immunotoxins 6.5.2 Fusion Protein Conjugates: Pipeline 2018 6.5.2.1 Moxetumomab Pasudotox 6.5.3 Humanised Immunotoxins 6.5.3.1 Using Granzyme B in Immunotoxins 6.5.3.2 Immunornases: A Future Development Opportunity for Immunotoxins 7. Next-Generation Insulin Submarket: Outlook to 2029 7.1 Strategies for Next-Generation Insulin Development 7.1.1 Reformulating Insulin for Convenient Administration 7.1.1.1 Oral Insulin 7.1.1.2 Inhaled Insulin 7.1.1.3 Exubera: A Failed Attempt at Reformulated Insulin 7.2 Next-Generation Insulin Submarket 2019-2029 7.2.1 Tresiba: Approved in the EU and Japan 7.2.1.1 Tresiba: Revenue Forecast 2019-2029 7.3 Next-Generation Insulin Submarket 2018-2029 7.3.1 Next-Generation Insulin Submarket Forecast 2018-2029 7.3.2 Product Launches in the US and EU Will Drive Submarket Growth 2019-2029 7.3.3 Next-Generation Insulin Submarket Restraints 2019-2029 7.3.3.1 Biosimilar Insulins are Available Since 2015 7.4 Oral Insulin Submarket 2019-2029 7.4.1 Oral Insulin Submarket Forecast 2019-2029 7.4.2 Oral Insulin: Submarket Drivers and Restraints 2019-2029 7.4.3 A Limited Clinical-Stage Pipeline for Oral Insulin 2018 7.4.3.1 Oramed Pharmaceuticals: Oral Insulin in Phase II 7.4.3.2 Oshadi Icp: Phase II Currently Recruiting 7.4.3.3 IN-105: Biocon Partners with Bristol-Myers Squibb for Development 7.4.3.4 Diabetology: Multiple Deals Signed for Emerging Markets 7.4.3.5 Novo Nordisk: NN-1953 7.5 Ultra-Rapid Acting Insulin Submarket 2019-2029 7.5.1 Ultra-Rapid Acting Insulin Submarket Forecast 2019-2029 7.5.1.1 Will Inhaled Insulins Drive Revenue Growth to 2029? 7.5.2 Other Submarket Drivers and Restraints 2019-2029 7.5.3 Ultra-Rapid Acting Insulin Pipeline 2018 7.5.3.1 FlAsp (Novo Nordisk) 7.5.3.2 Adocia: Eli Lilly Opts to Discontinue Partnership 7.5.3.3 Halozyme Therapeutics 7.5.3.4 Biodel: Multiple Ultra Rapid Acting Candidates 7.5.3.5 Afrezza: Inhaled Insulin Nearing the Market 7.5.3.6 Adagio: A Second-Generation Inhaled Insulin 7.6 Ultra-Long Acting Insulin Submarket 2019-2029 7.6.1 Ultra-Long Acting Insulin Submarket Forecast 2019-2029 7.6.2 Revenue Growth Driven by Uptake of Tresiba 7.6.3 Ultra-Long Acting Insulin Pipeline 2018 7.6.3.1 Toujeo: Sanofi's Next-Generation Insulin Analogue 7.6.3.2 LAPS-Insulin 8. Next-Generation Developments for Other Recombinant Proteins Forecast to 2029 8.1 Defining Next-Generation for Other Recombinant Protein Sectors 8.1.1 Next-Generation Interferon Beta: Plegridy Revenue Forecast 2019-2029 8.1.1.1 Plegridy May Compete With Other Long-Acting Interferon Beta Therapies 2019-2029 8.1.2 Next-Generation G-CSF: Teva Expands its Filgrastim Franchise 8.1.2.1 Other Clinical-Stages Advances in Filgrastim Therapy 2017 8.2 Next-Generation Recombinant Coagulation Factors 2019-2029 8.2.1 Next-Generation Recombinant Coagulation Factors Submarket Forecast 2019-2029 8.2.2 Submarket Drivers and Restraints 2019-2029 8.2.3 Clinical Pipeline for Recombinant Coagulation Factors 2019-2029 8.2.3.1 Fused Factors: Biogen Idec's Eloctate and Alprolix 8.2.3.2 Baxter's BAX 855 8.2.3.3 CSL Behring's rlX-FP: Albumin-Bound Coagulation Factors 8.2.3.4 Bayer's BAY94-9027 8.2.3.5 Novo Nordisk's N8-GP for Haemophilia A 8.2.3.6 Novo Nordisk's N9-GP for Haemophilia B 8.2.4 Gene Therapy as a New Treatment Option for Haemophilia 8.3 Next-Generation Growth Hormones 2019-2029 8.3.1 Next-Generation Growth Hormone Submarket Forecast 2019-2029 8.3.2 Brand Loyalty Will Restrain Uptake of Next-Generation Hormone 2019-2029 8.3.3 Long-Acting Growth Hormones 8.3.3.1 Biopartners/LG Life Sciences: The First Long-Acting Growth Hormone 8.3.3.2 Prolor Biotech/OPKO Health 8.3.3.3 Novo Nordisk: Looking to Extend its Market-Leading Position 8.3.3.4 Versartis: XTEN Technology for Half-Life Extension 8.3.4 Reformulated Growth Hormones: Offering Convenient Dosing for Paediatric Patients 8.3.4.1 Critical Pharmaceuticals: Nasal Delivery of Somatropin 9. Regenerative Medicine: Commercial Outlook to 2029 9.1 The Regenerative Medicine Submarket in 2018 9.1.1 Defining Regenerative Medicine 9.2 The Regenerative Medicine Submarket: Revenue Projections 2019-2029 9.2.1 Stem Cell and Gene Therapy Launches to Drive Growth 2019-2029 9.3 The Stem Cell Therapies Submarket 2019-2029 9.3.1 Prochymal (Mesoblast) for GvHD 9.3.1.1 The Future for Prochymal: Approval in Crohn's Disease? 9.3.1.2 A Note on Stem Cell Transplants 9.3.2 Stem Cell Therapies Submarket Forecast 2019-2029 9.3.3 Stem Cell Therapies: Submarket Drivers and Restraints 2019-2029 9.3.3.1 Will iPSCs Prove Effective for Stem Cell Therapy? 9.3.4 Stem Cell Therapies Late-Stage Pipeline 2018 9.3.4.1 Cx601 (TiGenix) 9.3.4.2 Mesoblast: Mesenchymal Stem Cell Therapies 9.3.4.3 Baxter Pharmaceuticals: A Leading Cardiovascular Candidate 9.3.4.4 StemEx (Gamida Cell) 9.4 Outlook for Tissue Engineering 2019-2029 9.4.1 Two Sectors Lead the Market: Wound and Cartilage Repair 9.4.1.1 Apligraf Leads the Wound Repair Submarket 9.4.1.2 Organogenesis Markets Apligraf and Dermagraft from 2014 9.4.2 Tissue Engineering Submarket Forecast 2019-2029 9.4.3 Tissue Engineering: Submarket Drivers and Restraints 2019-2029 9.4.4 Future Developments in Cartilage Repair: Pipeline 2018 9.4.5 Organ Repair and Engineering: The Next Step in Tissue Engineering? 9.4.5.1 Engineered Skin 9.4.5.2 Engineered Veins 9.4.5.3 Organ Transplant: A Long-Term Tissue Engineering Opportunity 9.5 The Gene Therapies Submarket 2019-2029 9.5.1 Glybera Approved and Set for Launch in the EU 9.5.2 Gene Therapies Submarket: Revenue Projections 2019-2029 9.5.3 Glybera's Approval Driving Submarket Growth Since 2014 9.5.4 There are More Than Five Gene Therapies in Late-Stage Development 9.5.4.1 ProstAtak: Gene Therapy for Prostate Cancer 9.5.4.2 TVEC (Amgen) 9.5.4.3 Generx (Cardium Therapeutics) 9.5.4.4 Spark Therapeutics: Established in 2013 for Ophthalmic Gene Therapy 10. Next-Generation Biologics: Industry Trends to 2029 10.1 Next-Generation Biologics: Market Strengths 2018 10.2 Next-Generation Biologics: Market Weakness 2018 10.3 The Next-Generation Biologics Market: STEP Analysis 2019-2029 10.3.1 Social Factors: Rising Disease Incidence and Demands for Convenience 10.3.1.1 Rising Incidence in Cardiovascular Disease, Cancer and Diabetes 10.3.1.2 Next-Generation Biologic Development in Emerging Markets 10.3.2 Technological Developments 2019-2029 10.3.3 Economic Pressures 2019-2029 10.3.3.1 High Drug Costs and Healthcare Spending 10.3.3.2 Limited Commercial Potential in Emerging Markets? 10.3.4 Political Issues: Regulatory Developments 2019-2029 10.4 Next-Generation Biologics: Development Trends 2019-2029 10.4.1 Improving Patient Convenience 10.4.2 Sustained Release Biologics: Pegylation and Beyond 10.4.3 Therapeutic Focus for Next-Generation Biologics 10.4.4 Next-Generation Biologics as Personalised Medicine 10.5 Manufacturing Challenges and Opportunities for Next-Generation Biologics 10.5.1 Contract Manufacturers Invest to Follow Development Trends 10.6 Commercialising Next-Generation Biologics 10.6.1 Product Lifecycle Management for First Generation Biologics 10.6.2 Proving Benefit in Next-Generation Products 10.6.3 Biosimilars as a Challenger 2019-2029 10.7 Partnering for Next-Generation Biologic Development 10.7.1 The Role of Big Pharma in the Next-Generation Biologics Market 10.7.2 Most Development Platforms Stem from Small Biotechs 11. Leading Manufacturers of Next-Generation Biologics 11.1 Eli Lilly and Company 11.1.1 Financial Overview 11.1.2 Key Developments 11.1.3 SWOT Analysis 11.2 F. Hoffmann-La Roche Ltd 11.2.1 Financials 11.2.2 Key Developments 11.2.3 SWOT Analysis 11.3 GlaxoSmithKline plc 11.3.1 Financial Overview 11.3.1 Key Developments 11.3.2 SWOT Analysis 11.4 Sanofi 11.4.1 Financial Overview 11.4.2 Key Developments 11.5 Abbvie 11.5.1 Financial Overview 11.5.2 Key Developments 11.5.3 SWOT Analysis 11.6 Amgen 11.6.1 Financial Overview 11.6.2 Recent Key Developments 11.6.3 SWOT Analysis 11.7 Novo Nordisk 11.7.1 Financial Overview 11.7.2 Key Developments 11.7.3 SWOT Analysis 11.8 Seattle Genetics 11.8.1 Financial Overview 11.8.2 SWOT Analysis 12. Conclusions from Our Research and Analysis 12.1 The Next-Generation Biologics Market Will Grow Strongly to 2029 12.2 Next-Generation Antibody Development Will Lead the Market 12.3 New Treatment Regimens Will Drive Demand for Next-Generation Biologics 12.4 Leading National Markets 12.5 Challenges Remain in Developing and Commercialising Next-Generation Biologics Appendices Associated Reports Visiongain Report Sales Order Form About Visiongain Visiongain Report Evaluation Form List of Tables Table 2.1 First Approvals for Recombinant Protein Therapies, 1982-1997 Table 3.1 Top Ten Bestselling Prescription Pharmaceuticals: Revenues ($bn), 2017 Table 3.2 Next-Generation Biologics Market: Revenues ($bn) & Market Share (%) by Sector, 2018 Table 3.3 Biological Drugs Market: Drivers and Restraints, 2019-2029 Table 3.4 Next-Generation Biologics Market: Overall Market Forecast and Revenue Forecasts ($bn), AGR (%), & CAGR (%) by Sector, 2019-2029 Table 3.5 Next-Generation Biologics: Market Shares (%) by Sector, 2019, 2024 and 2029 Table 4.1 Next-Generation Biologics Market: Revenues ($bn) by National Submarket, 2018 Table 4.2 National Incidence and Prevalence of Leading Indications Treated with Biologics (millions of patients), 2016 Table 4.3 Main Approval Dates for Next-Generation Biologics in Leading National Submarkets, 2003-2013 Table 4.4 Next-Generation Biologics Submarkets in the North America Nations: Revenues ($bn) & Market Share (%) 2018 Table 4.5 North America Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.6 North America Regenerative Medicine Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.7 North America Next-Generation Antibody Therapies Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.8 North America Next-Generation Antibody Fragments & ALPs Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.9 North America Next-Generation Insulin Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.10 US Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.11 Next-Generation Biologics Approval Table 4.12 Canada Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.13 Next-Generation Biologics Submarkets in the EU Nations: Revenues ($bn) & Market Share (%) 2018 Table 4.14 Europe Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.15 Europe Regenerative Medicine Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.16 Europe Next-Generation Antibody Therapies Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.17 Europe Next-Generation Antibody Fragments & ALPs Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.18 Europe Next-Generation Insulin Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.19 German Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.20 UK Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.21 France Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.22 Italian Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.23 Spanish Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%) 2019-2029 Table 4.24 Next-Generation Biologics Submarkets in the Asia Pacific Nations: Revenues ($bn) & Market Share (%) 2018 Table 4.25 Asia Pacific Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.26 Asia Pacific Regenerative Medicine Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.27 Asia Pacific Next-Generation Antibody Therapies Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.28 Asia Pacific Next-Generation Antibody Fragments & ALPs Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.29 Asia Pacific Next-Generation Insulin Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.30 Biosimilars Approved and Marketed in Japan, 2018 Table 4.31 Japanese Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.32 Chinese Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.33 Indian Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.34 Next-Generation Biologics Submarkets in RoW Nations: Revenues ($bn) & Market Share (%) 2018 Table 4.35 RoW Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.36 RoW Regenerative Medicine Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.37 RoW Next-Generation Antibody Therapies Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.38 RoW Next-Generation Antibody Fragments & ALPs Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.39 RoW Next-Generation Insulin Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.40 Brazil Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.41 Mexico Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.42 Russia Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 4.43 South Africa Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 5.1 Monoclonal Antibodies Submarket: Leading Drug Revenues ($bn), 2017 Table 5.2 Next-Generation Antibodies Submarket: Approved Drug Revenues ($bn), 2018 Table 5.3 Selected Clinical and Pre-Clinical ADC Platforms, 2018 Table 5.4 Selected Clinical and Pre-Clinical Engineered Antibody Platforms, 2018 Table 5.5 Next-Generation Antibodies Submarket: Revenues by Sector ($bn) & Market Share (%), 2018 Table 5.6 Next-Generation Antibodies Submarket: Overall Submarket Forecast and Revenue Forecasts ($bn), AGR (%), & CAGR (%), by Sector, 2018-2029 Table 5.7 Next-Generation Antibodies Submarket: Drivers and Restraints, 2019-2029 Table 5.8 Antibody Drug Conjugates Submarket: Revenues ($bn) and Submarket Shares (%) by Drug, 2018 Table 5.9 Antibody-Drug Conjugates Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029 Table 5.10 Kadcyla and Adcetris: Revenue Forecasts ($bn), 2018-2029 Table 5.11 Antibody-Drug Conjugates Submarket: Drivers and Restraints, 2019-2029 Table 5.12 Selected Antibody-Drug Conjugates in Phase III Development, 2018 Table 5.13 Selected Antibody-Drug Conjugates in Phase II Development, 2018 Table 5.14 Selected Antibody-Drug Conjugates in Phase I Development, 2018 Table 5.15 Engineered Antibodies Submarket Forecast ($bn), 2019-2029 Table 5.16 Gazyva/Gazyvaro: Revenue Forecast ($bn), 2018-2029 Table 5.17 Engineered Antibodies Submarket: Drivers and Restraints, 2019-2029 Table 5.18 Selected Engineered Antibodies in Phase II and III Development, 2018 Table 5.19 Bispecific Antibodies Submarket Forecast ($bn), 2019-2029 Table 5.20 Bispecific Antibodies Submarket: Drivers and Restraints, 2019-2029 Table 5.21 Bispecific Antibodies in Phase I and II Development, 2018 Table 6.1 Selected Next-Generation Antibody Fragment Platforms, 2018 Table 6.2 Selected Antibody-Like Protein Platforms, 2018 Table 6.3 Next-Generation Antibody Fragment and ALP Submarket: Overall Submarket Forecast and Revenue Forecasts ($bn), AGR (%) & CAGR (%), by Sector, 2019-2029 Table 6.4 Next-Generation Antibody Fragment and ALP Submarket: Drivers and Restraints, 2019-2029 Table 6.5 Next-Generation Antibody Fragment Submarket Forecast ($bn), AGR (%) & CAGR (%), 2018-2029 Table 6.6 Next-Generation Antibody Fragment Submarket: Clinical Pipeline, 2018 Table 6.7 Next-Generation Antibody-Like Protein Submarket Forecast ($bn), 2018-2029 Table 6.8 Next-Generation Antibody-Like Protein Submarket: Clinical Pipeline, 2018 Table 7.1 Tresiba: Revenue Forecast ($bn), AGR (%) & CAGR (%), 2018-2029 Table 7.2 Next-Generation Insulin Submarket: Overall Submarket Forecast and Revenue Forecasts ($bn) by Sector, 2019-2029 Table 7.3 Next-Generation Insulin Submarket: Drivers and Restraints, 2019-2029 Table 7.4 Diabetes: Prevalence and Proportion of Population Affected, 2016 Table 7.5 Leading Insulin Analogues: US and EU Patent Expiries, 2013-2019 Table 7.5 Oral Insulin Submarket Forecast ($bn), & CAGR (%) 2019-2029 Table 7.6 Oral Insulin Submarket: Drivers and Restraints, 2019-2029 Table 7.7 Oral Insulin: Selected Pre-Clinical and Clinical-Stage Pipeline, 2018 Table 7.8 Ultra-Rapid Acting Insulin Submarket Forecast ($bn), 2019-2029 Table 7.9 Ultra-Rapid Acting Insulin Submarket: Drivers and Restraints, 2019-2029 Table 7.10 Ultra-Rapid Acting Insulin: Pre-Clinical and Clinical-Stage Pipeline, 2018 Table 7.11 Afrezza: Revenue Forecast ($bn), AGR (%) & CAGR (%), 2018-2029 Table 7.12 Ultra-Long Acting Insulin Forecast ($bn) AGR (%) & CAGR (%), 2019-2029 Table 7.13 Ultra-Long Acting Insulin Submarket: Drivers and Restraints, 2019-2029 Table 7.14 Selected Ultra-Long Acting Insulin: Clinical-Stage Pipeline, 2018 Table 8.1 Plegridy: Revenue Forecast ($bn), AGR (%) & CAGR (%), 2018-2029 Table 8.2 Recombinant Coagulation Factor Half-Lives and Target Populations, 2018 Table 8.3 Next-Generation Recombinant Coagulation Factors Submarket Forecast ($bn), AGR (%) & CAGR (%), 2018-2029 Table 8.4 Next-Generation Recombinant Coagulation Factors Submarket: Drivers and Restraints, 2019-2029 Table 8.5 Long-Acting Recombinant Factors VIII and IX in Late-Stage Clinical Development, 2018 Table 8.6 Eloctate: Revenue Forecast ($bn), AGR (%) & CAGR (%), 2018-2029 Table 8.7 Alprolix: Revenue Forecast ($bn), 2019-2029 Table 8.8 Next-Generation Growth Hormones Submarket Forecast ($bn), 2019-2029 Table 8.9 Next-Generation Growth Hormones Submarket: Drivers and Restraints, 2019-2029 Table 8.10 Selected Next-Generation Growth Hormones in Clinical Development, 2018 Table 9.1 Regenerative Medicine Submarket: Revenues by Sector ($bn) & Submarket Share (%) 2018 Table 9.2 Regenerative Medicine Submarket: Overall Submarket Forecast and Revenue Forecasts ($bn), AGR (%) and CAGR (%) by Sector, 2018-2029 Table 9.3 Regenerative Medicine Submarket: Drivers and Restraints, 2019-2029 Table 9.4 Stem Cell Therapies Submarket Forecast ($bn), AGR (%) & CAGR (%), 2018-2029 Table 9.5 Stem Cell Therapies Submarket: Drivers and Restraints, 2019-2029 Table 9.6 Selected Stem Cell Therapies in Phase II and III Clinical Trials, 2018 Table 9.7 Selected Stem Cell Therapies in Phase I/II Development, 2018 Table 9.8 Tissue Engineering Submarket Forecast ($bn), AGR (%) & CAGR (%), 2018-2029 Table 9.9 Tissue Engineering Submarket: Drivers and Restraints, 2019-2029 Table 9.10 Gene Therapies Submarket Forecast ($bn), AGR (%) & CAGR (%), 2018-2029 Table 9.11 Gene Therapies Submarket: Drivers and Restraints, 2019-2029 Table 9.12 Gene Therapies in Phase II and III Clinical Trials, 2018 Table 10.1 Next-Generation Biologics: STEP Analysis, 2019-2029 Table 10.2 Selected CMO Investments in Next-Generation Biologics, to 2018 Table 12.1 Next-Generation Biologics Market: Submarket Forecasts ($bn) and Market Shares (%), 2018, 2024 and 2029 Table 12.2 Next-Generation Biologics Market: Revenues ($bn) by National Submarket, 2018 List of Figures Figure 1.1 Next-Generation Biologic Market Segmentation, 2017 Figure 3.1 Next-Generation Biologics: Market Shares (%) by Sector, 2018 Figure 3.2 Next-Generation Biologics Market: Revenue Forecast ($bn), 2019-2029 Figure 3.3 Next-Generation Biologics: Market Drivers, 2018-2028 Figure 3.4 Next-Generation Biologics: Market Restraints, 2018-2029 Figure 3.5 Next-Generation Biologics: Market Shares (%) by Sector, 2018-2029 Figure 4.1 Next-Generation Biologics: Market Shares (%) by Country, 2019 Figure 4.2 Next-Generation Biologics: Market Revenue ($bn) by Country, 2018-2029 Figure 4.3 Next-Generation Biologics: Market Shares (%) by Country, 2018-2029 Figure 4.4 North America Region: Next-Generation Biologics Submarket Shares (%), 2018-2029 Figure 4.5 US Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2018-2029 Figure 4.6 Canada Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2018-2029 Figure 4.7 EU Region: Next-Generation Biologics Submarket Shares (%), 2018-2029 Figure 4.8 German Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2018-2029 Figure 4.9 UK Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2018-2029 Figure 4.10 French Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2018-2029 Figure 4.11 Italian Next-Generation Biologics Submarket Forecast ($bn), 2019-2029 Figure 4.12 Spanish Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2018-2029 Figure 4.13 Asia Pacific Region: Next-Generation Biologics Submarket Shares (%), 2018-2029 Figure 4.14 Japanese Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2018-2029 Figure 4.15 Chinese Next-Generation Biologics Submarket Forecast ($bn) &AGR (%), 2019-2029 Figure 4.16 Indian Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2018-2029 Figure 4.17 RoW Region: Next-Generation Biologics Submarket Shares (%), 2018-2029 Figure 4.18 Brazil Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2018-2029 Figure 4.19 Mexico Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2018-2029 Figure 4.20 Russia Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2018-2029 Figure 4.21 South Africa Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2018-2029 Figure 5.1 Next-Generation Antibodies: Submarket Shares (%) by Sector, 2018-2029 Figure 5.2 Next-Generation Antibodies Submarket Forecast ($bn), 2018-2029 Figure 5.3 Antibody-Drug Conjugates: Submarket Shares (%) by Drug, 2018 Figure 5.4 Kadcyla Revenue Forecasts ($bn) & AGR (%), 2019-2029 Figure 5.5 Adcetris: Revenue Forecasts ($bn) & AGR (%), 2019-2029 Figure 6.1 Next-Generation Antibody Fragment and ALP Submarket Forecast ($bn) & AGR (%), 2018-2029 Figure 6.2 Next-Generation Antibody Fragment Submarket Forecast ($bn), 2018-2029 Figure 6.3 Next-Generation Antibody-Like Protein Submarket Forecast ($bn), 2018-2029 Figure 7.1 Tresiba: Revenue Forecast ($bn), & AGR (%), 2019-2029 Figure 7.2 Next-Generation Insulin Submarket Revenue Forecast ($bn), 2019-2029 Figure 7.3 Diabetes: Proportion of Population Affected, 2016 Figure 7.4 Oral Insulin Submarket Forecast ($bn), 2019-2029 Figure 7.5 Ultra-Rapid Acting Insulin Submarket Forecast ($bn), 2019-2029 Figure 7.6 Afrezza: Revenue Forecast ($bn), 2019-2029 Figure 7.7 Ultra-Long Acting Insulin Submarket Forecast ($bn) & AGR (%), 2018-2029 Figure 8.1 Plegridy: Revenue Forecast ($bn) & AGR (%), 2018-2029 Figure 8.2 Next-Generation Recombinant Coagulation Factors Submarket Forecast ($bn) & AGR (%), 2018-2029 Figure 8.3 Eloctate: Revenue Forecast ($bn), 2019-2029 Figure 8.4 Alprolix: Revenue Forecast ($bn), 2019-2029 Figure 8.5 Next-Generation Growth Hormones Submarket Forecast ($bn), 2019-2029 Figure 9.1 Regenerative Medicine: Submarket Shares (%) by Sector, 2018-2029 Figure 9.2 Regenerative Medicine Submarket Forecast ($bn) & AGR (%), 2018-2029 Figure 9.3 Stem Cell Therapies Submarket Forecast ($bn) & AGR (%), 2018-2029 Figure 9.4 Tissue Engineering Submarket Forecast ($bn) & AGR (%), 2018-2029 Figure 9.5 Gene Therapies Submarket Forecast ($bn) & AGR (%), 2018-2029 Figure 10.1 Big Pharma Partnering Opportunities for Next-Generation Biologics Development, 2018 Figure 11.1 Eli Lilly and Company Revenue ($mn), 2014-2017 Figure 11.2 Roche Revenue ($bn) & AGR (%) 2016-2018 Figure 11.3 GSK Revenue ($mn), 2014-2017 Figure 11.4 Sanofi Revenue ($bn) & AGR (%) 2014-2017 Figure 11.5 AbbVie Revenue ($bn) & AGR (%) 2014-2017 Figure 11.6 Amgen Revenue ($bn) & AGR (%) 2015-2018 Figure 11.7 Novo Nordisk Revenue ($mn) & AGR (%) 2015-2018 Figure 11.8 Revenue ($bn) & AGR (%) 2014-2018 Figure 12.1 Next-Generation Biologics Market: Revenue Forecast ($bn), 2018, 2024, & 2029